
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

Proposals are due May 1!
Grants for Technology Product Development
Market-driven new technology and innovation leads to new products and new jobs. Creating jobs in innovative Maryland companies is what the Maryland Industrial Partnerships (MIPS) program has been doing for 32 years: bringing the inventive minds and extensive laboratory resources of the University System of Maryland (USM) to bear on creating the new products that feed the growth of Maryland businesses. Since the program’s inception in 1987, MIPS–enabled products have generated sales of $40 B. MIPS is nationally recognized by the U.S. Small Business Administration as a model program for best practices in transferring technology and is a proven program that contributes significantly to job creation and high tech product development in Maryland.

Partnership Announced to Distribute High Potency Probiotic in Mexico to Support Patients with Gut Microbiome Imbalance
Rockville, M.D., and Charlotte, N.C., April 12, 2023 – ExeGi Pharma LLC (“ExeGi”), a leading developer of live biotherapeutic drugs and probiotics, has announced a partnership with TannerLAC, Inc. (“TannerLAC”), a division of Tanner Pharma Group, to distribute Visbiome® in Mexico. Visbiome® is a high-potency probiotic medical food that helps manage dysbiosis associated with medical conditions like irritable bowel syndrome and ulcerative colitis. With eight probiotic strains delivered in high potency, Visbiome® is one of the most extensively researched probiotics on the market, with over 80 human clinical trials performed over the last 20 years. The formulation is available in more than 40 countries.

April 11, 2023 at 7:30 AM EDT
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B (CHB). With the achievement of this milestone, data readout is planned for the first quarter of 2024.
The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen (HBsAg). Subjects were randomized 1:1 to HepTcell or placebo. The primary endpoint of the trial is clinical response, defined as a 1-log or greater reduction in HBsAg. Secondary endpoints include changes in the levels of hepatitis B virus (HBV) DNA, pre-genomic RNA and other markers of virologic response.

RGX-202 is a potential one-time AAV Therapeutic for the treatment of Duchenne and includes an optimized transgene for a novel microdystrophin and REGENXBIO’s proprietary NAV® AAV8 vector
- Commercial-scale cGMP material from the REGENXBIO Manufacturing Innovation Center to be used in the clinical trial
- AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 is active and recruiting patients; anticipated to report initial trial data in the second half of 2023
ROCKVILLE, Md., April 11, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne).

The Biden administration has announced a $5 billion program to accelerate the development of next-generation COVID-19 vaccines and treatments.
Like Operation Warp Speed, which developed and distributed vaccines in the early days of the pandemic, Project NextGen will cut across government agencies and involve public-private collaborations, a senior Biden official told USA TODAY.
Image: https://www.usatoday.com – From Video

BioHealth Innovation’s Renée Arnold is set to lead an insightful panel discussion at the upcoming ISPOR 2023 conference, which will take place on May 8, 2023, one at 12:45 and the other at 3:15 pm. The session, “Blazing The Trail for Digital Health Innovation: Resources and Examples Based on a Digital Health Application for Dementia Family Caregivers,” aims to shed light on digital health technologies’ research and development pathway. It will also cover the evolving US regulations framing evidence requirements for the approval of digital health applications.

A Baltimore startup that helps get patients to take their medications has raised one of the largest funding rounds in Baltimore so far this year.
Scene Health announced Wednesday the closure of a $17.7 million series B round led by ABS Capital Partners with participation from Claritas Health Ventures, Healthworx, the innovation arm of CareFirst BlueCross BlueShield, PTX Capital and Kapor Capital. The company is planning to move into an office in North Baltimore this year after it closed its Mount Vernon office during the pandemic.

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|